Affimed to Present at Upcoming Investor Conferences

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) announced participation in two upcoming investor conferences in November 2021. The Stifel 2021 Virtual Healthcare Conference will be held from November 15-17, 2021, with a presentation on the 15th at 8:00 a.m. EST. The Jefferies London Healthcare Conference takes place from November 16-19, 2021, featuring a fireside chat available on November 18 at 3:00 a.m. EST. Affimed is dedicated to advancing immuno-oncology therapies, leveraging its proprietary ROCK® platform to develop novel treatments for cancer.

HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of November 2021.

Stifel 2021 Virtual Healthcare Conference (November 15 - 17, 2021)
Date: Monday, November 15, 2021
Presentation Time: 8:00 a.m. EST
Webcast: https://www.affimed.com/investors/webcasts_cp/
Location: Virtual

Jefferies London Healthcare Conference 2021 (November 16 - 19, 2021)
Date: Friday, November 19, 2021
Presentation Time: The Fireside Chat will become available on November 18 at 3:00 a.m. EST
Webcast: https://www.affimed.com/investors/webcasts_cp/
Location: Virtual

For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK^® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK^® platform predictably generates customized innate cell engager (ICE^®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE^®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: https://www.affimed.com.

Affimed Investor Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

What investor conferences will Affimed (AFMD) participate in during November 2021?

Affimed will participate in the Stifel 2021 Virtual Healthcare Conference from November 15-17 and the Jefferies London Healthcare Conference from November 16-19.

When is Affimed's presentation at the Stifel Conference?

Affimed's presentation at the Stifel Conference is scheduled for November 15, 2021, at 8:00 a.m. EST.

What is Affimed's (AFMD) approach to cancer treatment?

Affimed utilizes its proprietary ROCK® platform to develop therapies that empower the innate immune system to combat cancer.

When will the fireside chat at the Jefferies Conference be available?

The fireside chat at the Jefferies London Healthcare Conference will be available on November 18, 2021, at 3:00 a.m. EST.

How can investors contact Affimed for one-on-one meetings?

Investors can schedule one-on-one meetings with Affimed management by contacting their conference representative or reaching out to Alex Fudukidis via email.